Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: Hep C Treatments in Current Clinical Development - Quick Ref Guide


Guru

Status: Offline
Posts: 678
Date:
RE: Hep C Treatments in Current Clinical Development - Quick Ref Guide
Permalink  
 


looks like they are looking for a NS5a protease blocker and an alt for the polymerase blocker. The NS5b protease blocker must be satisfactory.


__________________

  HCV Genotype 3a , now Psot-Tx was on S/riba. First VL was 5.8 mil on 7-5-13 then "und" at 3.8 weeks. 06/13/14 still und. off meds 3 days back on 7/29 Last pill 08/10/14 SVR+4

 



Senior Member

Status: Offline
Posts: 210
Date:
Permalink  
 

Wow, Jill.  Just saw this posting.  What a great resource!



__________________

Dx. 2005-liver bx.: stg 2/gr 1. at that time  - GT 1a multiple transfusions in 1981.  Started Sovaldi and Olysio 1/16/14  (No prior treatments) Q80K present.  UND week 4,8 and at EOT.   UND at wk 4EOT, Und at wk 8EOT  SVR 12!!!..SVR 24 :-)



Guru

Status: Offline
Posts: 1724
Date:
Permalink  
 

Excellent information.  Thanks!



__________________

Diagnosed in 2011, Incivek triple in 2011, tx discontinued, Genotype 1a, CT, VL 7mill, cirrhosis dx in 2012, age 67, waiting for new DAAs.



Guru

Status: Offline
Posts: 5627
Date:
Permalink  
 

A quick reference guide to Hep C drugs currently in clinical development, updated 11th June 2014.

Fom the HCV Advocate website, in pdf format....

http://www.hcvadvocate.org/hepatitis/hepC/Quick_Ref_Guide.pdf



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.